LIVERMORE, Calif., October 18/PRNewswire/--after Medical, Inc. announced today that it has been approved in Canada for Tulip ™ sentyyppisestä flask Thermal ablation (RFVTA)-the placing on the market of the probe. "We've just received Health Canada license for puts us closer to our goal, is an important step in making available to the women in North America, which suffer from poor millions of our rotissa rotissa sparing procedure," said Russ, President and CEO of DeLonzor, stop the Medical. "Approvals in Canada and you have now received the European Union and for general use, as well as our recent rotissa poor to the global market for use in dentistry (is not separately reported poor) Administration in the United States, our products, THE FDA is us very well placed in the brokering activities to bring our solutions for most of the major global markets in the near future," said DeLonzor.
Information about the audit of the Medical, Inc.
Stop the Medical, Inc. is a medical device which forms part of a planning and close to San Francisco, CA the manufacture of products from developing countries, the company for the next generation of RFVTA ablate tissues with the system.Audit of the system for general use, THE FDA has been cleared and is currently in the United States and Latin America, the relief shall continue to be problems caused by poor rotissa. Stop prepares commercialised stop Fibroid System on the market, if it has already been approved for general surgical and fibroid indications outside the United States, the global business opportunity to stop the. Fibroid System more than $ 2billion is estimated to be on an annual basis.
For information about how to stop the fibroid, clinical research and a list of strings, numbers, in the United States at www.clinicaltrials.gov NCT00874029 research.
SOURCE after Medical, Inc.
Back to the beginning of theRELATED LINKS
http://www.haltmedical.com
No comments:
Post a Comment